ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 937,90
-0,75%
Dow Jones
38 711,29
0,36%
DAX
18 405,64
-1,10%
Brent Oil
77,455
0,45%
Bitcoin
71 008,47
0,63%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) Actualités

NKTR Nektar Therapeutics

1,40
-0,01 (-0,71%)
05 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nektar Therapeutics NKTR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,01 -0,71% 1,40 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,36 1,32 1,43 1,40 1,41
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
31/5/202400:00PRNUSNektar Management to Present at Upcoming Investor..
28/5/202422:51EDGAR2Form S-3 - Registration statement under Securities Act of..
21/5/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202403:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202403:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:25EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:22EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:14EDGAR2Form 144 - Report of proposed sale of securities
13/5/202422:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:20EDGAR2Form 8-K - Current report
09/5/202422:15PRNUSNektar Therapeutics Reports First Quarter 2024 Financial..
03/5/202400:00PRNUSNektar to Announce Financial Results for the First Quarter..
22/3/202419:00PRNUSNektar Management to Present at the H.C. Wainwright 2nd..
05/3/202423:11EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202415:00PRNUSNektar Therapeutics Announces Initiation of Phase 2b..
04/3/202422:20EDGAR2Form 8-K - Current report
04/3/202422:15PRNUSNektar Therapeutics Reports Fourth Quarter and Year-End 2023..
04/3/202414:40EDGAR2Form 8-K - Current report
04/3/202414:30PRNUSNektar Therapeutics Announces $30 Million Private Placement..
28/2/202400:00PRNUSNektar Management to Present at the TD Cowen 44th Annual..
27/2/202400:00PRNUSNektar to Announce Financial Results for the Fourth Quarter..
23/2/202402:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202421:55EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:51EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:50EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:16EDGAR2Form 8-K - Current report
14/2/202423:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202422:25EDGAR2Form 8-K - Current report
04/1/202400:00PRNUSNektar Management To Present at the 42nd Annual J.P. Morgan..
16/12/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202318:18EDGAR2Form 144 - Report of proposed sale of securities
12/12/202300:00PRNUSNektar and Collaborators Present Preclinical Data on..
27/11/202322:55EDGAR2Form 8-K - Current report
21/11/202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202302:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202322:36EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:15EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:10EDGAR2Form 144 - Report of proposed sale of securities
07/11/202322:21EDGAR2Form 8-K - Current report
07/11/202322:15PRNUSNektar Therapeutics Reports Third Quarter 2023 Financial..
31/10/202323:00PRNUSNektar to Announce Financial Results for the Third Quarter..
13/10/202314:30PRNUSNektar Presents New Responder Data for Rezpegaldesleukin, a..
02/10/202315:00PRNUSNektar Therapeutics Announces Two Abstracts Accepted at EADV..
27/9/202315:00PRNUSNektar Therapeutics Announces New Clinical Study..

Dernières Valeurs Consultées

NASDAQ
NKTR
Nektar Therapeutics
BIT
EGB5
ETFS 5x Long GBP Short EUR
COIN
SPLUST
Splash
NYSE
NSC
Norfolk Southern
LSE
58QB
Rep. Ken 34 U
BIT
P1WTY5
NLBNPIT1WTY5 20240918 17...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés